Cite
HARVARD Citation
Clemons, M. et al. (n.d.). LBA 3A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases. Annals of oncology. p. . [Online].